Quick context
ARA-290 / Cibinetide
临床研究涉及炎症、神经及代谢结局；尚无普遍药品批准。
Published study protocols are research procedures with inclusion and exclusion criteria. They are not instructions for unsupervised use.
Back to all 64 profiles
Clinical research临床研究中WADA
Community protocol · ARA-290 / Cibinetide
ARA-290 / Cibinetide: community information and evidence, clearly separated.
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: ARA 290 · Cibinetide · pHBSP
Sources checked: 27 August 2026
重要安全与责任声明
本页记录并评估网络社区信息，不构成医疗或治疗建议、个体咨询，也不是使用邀请。
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Amounts, timing and cycles
Clinical research
Published study protocols are research procedures with inclusion and exclusion criteria. They are not instructions for unsupervised use.
Amount status
Trials use protocol-bound amounts and escalation; this does not create a safe community dose.
Profile evidence level: clinical.
Timing
Timing is set by each trial protocol and may differ substantially between studies.
No individual recommendation.
Cycle/duration
Duration is study-specific and ends according to protocol; long-term safety may remain unknown.
No individual recommendation.
External community reference available
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Open community source复配与 U-100 换算
复配计算器
For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.
复配计算器
Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.
Concentration
3,333.33 µg/ml
Calculated volume
0.06 ml
U-100 units
6 U
Calculated portions per vial
50
Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.
Mechanism and research questions
Non-haematopoietic erythropoietin-derived tissue-protective peptide
ARA-290 / Cibinetide is classified as “Non-haematopoietic erythropoietin-derived tissue-protective peptide”. 临床研究涉及炎症、神经及代谢结局；尚无普遍药品批准。 This describes the investigated pathway but does not validate a community use, amount, route or combination.
源自EPO的组织保护
这项研究考察源自促红细胞生成素的片段是否能在不具备原激素造血活性的情况下提供组织保护,类似于只保留多项功能中一项的部分。在实验室模型中测量细胞存活率和炎症标志物。
神经保护信号传导
这项研究考察某物质是否能保护神经细胞免受压力或损伤,例如在细胞模型中缺氧后的情况。在实验室条件下测量神经组织中的细胞存活率和信号标志物。
免疫调节肽
这项研究考察某肽如何调节免疫细胞活性,类似于增强或抑制免疫反应的旋钮。研究中测量免疫细胞计数和炎症标志物。
What communities discuss
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
恢复与损伤论坛
人们比较在使用不同修复肽时运动损伤后的个人恢复时间,通常基于主观疼痛量表。这类个体经历受许多其他因素影响,并不能证明疗效。
生物黑客与长寿论坛
用户比较自行组合的肽方案,以期影响衰老过程或能量水平,常常依据血液检测或主观幸福感量表。个人自我实验和营销承诺无法取代对照的长期人体研究。
来源与纯度讨论
人们讨论哪些商家被认为更值得信赖,以及不同批次之间纯度检测结果的差异。这类社区评估基于有限的样本,无法替代对每一批次进行的独立实验室检测。
Adverse effects and risk boundaries
- 许多所谓修复肽缺乏对照人体研究。未知全身效应、免疫反应、出血或血管影响，以及注射相关感染和污染仍是核心风险。
- Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
- A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.
Exclusion groups and professional assessment
- 妊娠、癌症、活动性感染、凝血障碍、计划手术及相关免疫疾病需要特别严格的专业评估或避免使用。
- Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
- Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.
Monitoring and laboratory markers
- 未获批修复肽没有经过验证的监测方案。根据具体问题，临床表现、炎症征象、血常规、肝肾功能及凝血可能相关。
- Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.
Evidence boundary
临床试验中
尽管有临床研究,但仍缺乏普遍的药品批准。
Published evidence
该物质目前正在结构化的人体临床试验中进行研究,尚未获得普遍批准。
ARA-290源自促红细胞生成素,但不具备其生血作用,不同于经典的EPO产品。
Storage and stability
- The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
- Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
- Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.
Troubleshooting and error sources
- U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
- Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
- Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
- Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.
Regulatory status and WADA
临床研究中
处于临床开发阶段，尚不是获批药物。
WADA 2026
This profile is marked as WADA-relevant. Check the original 2026 Prohibited List and the specific sport/route; a prohibition may cover an entire class or related agents.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
- Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
- Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
- Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.
Frequently asked questions
Is an amount shown here a recommendation?
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
Does the U-100 calculator prove correct use?
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Can this profile be combined with other substances?
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
Which source controls when information conflicts?
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
Are community claims clinical evidence?
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
- Primary/technical sourceClinicalTrials.gov: ARA-290
- Primary/technical sourceBrines et al. — Cibinetide clinical study
- Primary/technical sourceWADA — 2026 Prohibited List
- Community referenceARA-290 / Cibinetide — Peptide Dosing Protocols